SVF for Aerodigestive and Enterocutaneous Fistulae

Phase 1, open-label, single-arm trial of autologous adipose stromal vascular fraction in tracheoesophageal fistula (TEF), Bronchoesophageal fistula (BOF), enterocutaneous fistula (ECF) and 1 more, sponsored by Mayo Clinic. Primary endpoints: Adverse Events from a single dose of autologous stromal vascular fraction at 5 years and Adverse Events from liposuction procedure at 5 years. Planned start Feb 2021; status: withdrawn.